Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: A study by the gruppo italiano studio linfomi

Donato Mannina, Stefano Luminari, Alessandra Dondi, Giuseppe Polimeno, Luca Baldini, Caterina Stelitano, Francesco Merli, Matteo Dell'Olio, Paolo G. Gobbi, Gianfranco Giglio, Elisa Barbolini, Maura Brugiatelli, Massimo Federico

Research output: Contribution to journalArticle


We conducted a retrospective analysis on 168 adult patients with newly diagnosed, limited-stage (I and II) diffuse large B-cell lymphoma (DLBCL) treated from 1988 to 2004 with PROMECE-CYTABOM (P-C) plus involved-field radiation therapy (IF-RT). At the end of P-C, the overall response rate was 92. Radiotherapy (RT) was delivered to 84 of cases. With a median follow-up of 95 months, overall survival (OS), relapse free survival (RFS), and failure free survival at 5 and 10 years was 84 and 77, 81 and 75, 71 and 67, respectively. Age (>60 years, p0.002), serum albumin (

Original languageEnglish
Pages (from-to)422-429
Number of pages8
JournalLeukemia and Lymphoma
Issue number3
Publication statusPublished - 2010



  • Chemotherapy
  • Localized lymphoma
  • Outcome
  • Radiotherapy
  • Retrospective analysis
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this